《大行報告》高盛下調中國飛鶴(06186.HK)目標價至16.8元 評級「買入」
高盛發表研究報告指出,隨着近期新生兒數量持續下跌,預期2022至2023年中國嬰兒配方奶粉行業增長將面臨短期壓力,而由於嬰兒數量減少,該行預期2022至2023財年配方奶粉銷量分別下降8%及5%,期後才轉向穩定。
該行將中國飛鶴(06186.HK)2021至2023財年的每股盈利預測下調4至7%,以反映行業增長放緩,惟仍預期公司可實現其目標,並有穩固的市場份額增長(2023財年年底前約爲30%)。雖然該股估值較低,但目前股價相當於2022財年市盈率約8.9倍,遠低於其約18倍的歷史平均水平。維持「買入」評級,目標價由23.3元降至16.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.